Contact the committee
Contact the committee c/o RCPsych committees
His research interests centre on the causes and treatment of psychosis. His recent work has focussed on understanding the role of dopamine and neuroinflammation in the development of psychosis, the effects of antipsychotic drugs on the nervous and endocrine systems, & the causes of cognitive impairment in schizophrenia. This work has been recognised through a number of awards including the Schizophrenia International Research Society Rising Star Award 2013, European Psychiatric Association Biological Psychiatry Prize (2012), the Royal Society of Medicine Psychiatry Prize (2010), Royal College of Psychiatrists research prize (2005), and the British Association of Psychopharmacology Clinical Psychopharmacology Prize (2007). He was made an honorary associate of the European College of Neuropsychopharmacology in 2006.
Other career highlights include working as a junior potato scrubber on a farm. He spends his spare time selflessly trying to find the world’s best ice cream.
Declaration of interests
Employed part-time by King’s College London and part-time by H Lundbeck A/v and Honorary Consultant at SLaM (NHS UK).
No share holdings in pharmaceutical or medical device companies.
Has received funding from Astra-Zeneca, Autifony, BMS, Eli Lilly, Heptares, Invicro, Jansenn, Lundbeck, Mylan (Viatris), Neurocrine, Otsuka, Servier, Sunovion, Rand, and Roche for investigator initiated studies and/or for participation in advisory boards, speaker bureau and/or educational events.
Main grant funding (past and present): MRC (UK), Wellcome Trust, and European Union.
I am Professor of Clinical Psychiatry at Imperial College, London, Honorary Consultant Psychiatrist at the West London Mental Health NHS Trust, and joint-head of the Prescribing Observatory for Mental Health (POMH-UK).
In 1987, I set up one of the first tertiary-referral services for treatment-resistant schizophrenia. The main focus of my clinical research over the last 30 years has been schizophrenia, with a particular interest in the rational treatment of the condition. I have led investigations that have covered psychological and pharmacological treatment interventions for the condition and investigated antipsychotic drug side effects (particularly extrapyramidal movement disorders; the reliability, validity and clinical utility of the Barnes Akathisia Rating Scale have been independently demonstrated, and it is the scale most frequently used to assess this condition, world-wide), as well as phenomenology, neurocognition and comorbid substance use, including a Wellcome-funded, first-episode psychosis study. My work has generated over 250 publications.
Recent research experience includes PI for the CUtLASS trial, and chair of the IDMECs for the BALANCE and CEQUEL trials. I am currently CI for the HTA-funded ACTIONS and AMICUS trials, PI for the BeneMin study, and chair of the Trial Steering Committees for the NESS and CIRCLE studies. I am a past member of the Committee on Safety of Medicines, past Chair of the Royal College of Psychiatrists’ Special Interest Group in Psychopharmacology, and past President of the British Association for Psychopharmacology. I was a member of the NICE schizophrenia guideline development group (and chair of the pharmacology subcommittee) in 2002 and for the guideline update in 2009.
Sam Chamberlain is a Wellcome Trust Fellow and Honorary Consultant Psychiatrist, at the University of Cambridge Department of Psychiatry, and Cambridge & Peterborough NHS Foundation Trust. His work focuses on the neurobiology and treatment of impulsive, compulsive, and behaviourally-addictive disorders. Key examples include attention-deficit hyperactivity disorder (ADHD), obsessive-compulsive disorders, and gambling disorder. These conditions are common, functionally impairing, but often hidden and under-treated.
Dr Chamberlain’s research uses clinical measures, cognitive tests, and biomarkers (such as brain imaging and genetics) to better understand why impulsive and compulsive problems develop; and how they can be better treated. He has contributed to the development of new clinical rating scales / instruments; and to a number of treatment studies. For example, along with collaborators in the USA, he found that n-acetyl cysteine (an antioxidant and amino-acid precursor) improved symptoms of skin picking disorder; and enhanced long-term outcomes when used alongside psychotherapy in gambling disorder.
Dr Chamberlain has published widely, including first-authored papers in Science, the American Journal of Psychiatry, Biological Psychiatry, and the Archives of General Psychiatry. He is co-author of several books including ‘Clinical Guide to Obsessive Compulsive and Related Disorders' and ‘Why Can't I Stop? Reclaiming Your Life from a Behavioral Addiction’. He is Associate Editor at Neuroscience and Biobehavioral Reviews, and acts as reviewer for a variety of journals and organizations. Dr Chamberlain has received the Wyeth Award for Psychopharmacology from the British Association for Psychopharmacology, and a Clinical Fellowship from the Wellcome Trust.
Professor McAllister-Williams has been employed by Newcastle University since 1995, initially as a Clinical lecturer, then as an MRC Clinician Scientist Fellow and subsequently a Reader in Clinical Psychopharmacology. In 2017 he was promoted to a Personal Chair. Clinically, he is the lead consultant in the tertiary level Regional Affective Disorders Service based in Newcastle. This is the oldest and one of the largest such service in the UK providing outpatient and inpatient services for patients with treatment refractory mood disorders. Referrals to the service are received from across the UK and internationally. Professor McAllister-Williams research focuses on the pathophysiology and treatment of both bipolar and unipolar affective disorders. He is a past General Secretary of the British Association for Psychopharmacology (BAP) and was appointed in 2012 as the BAP Director of Education. He is a major contributor to their CPD programme.
Declaration of interests
Professor McAllister-Williams has received speaker and consultancy fees, support for attending meetings and independent investigator led research awards from a number of pharmaceutical companies over several years including AstraZeneca, Bristol Myers-Squibb, Cyberonics, Eli Lilly, Ferrer, GlaxoSmithKline, Janssen-Cilag, LivaNova, Lundbeck, Merck Sharp & Dohme, My Tomorrows, Otsuka, Pfizer, Roche, Servier, SPIMACO, Sunovion and Wyeth. The vast majority of such monies have been paid to his employer, Newcastle University. Neither he nor any of his immediate family hold any shares in, or have on-going financial relationships with, any pharmaceutical company.
Dr Eleanor Smith is a Consultant Child and Adolescent Psychiatrist for Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust and an Associate Clinical Lecturer at Newcastle University. In her clinical role Dr Smith is the Consultant Psychiatrist for the Complex Neurodevelopmental Disorder Service (CNDS). Based in Newcastle upon Tyne, CNDS is an Autism Spectrum Disorder (ASD) clinical academic service funded by NHS England to provide second opinion diagnostic assessments and consultation/management advice for autistic children and young people with co-morbid psychiatric disorder who require more specialist intervention than is available within local child and adolescent mental health and paediatric services.
Dr Stokes has received research funding support from Corcept Therapeutics Inc. He has received grant funding from the Medical Research Council UK for a collaborative study with Janssen Research and Development LLC. Janssen Research and Development LLC are providing non-financial contributions to support this study. Dr Stokes has received expenses to attend conferences, and fees for lecturing and consultancy work (including attending an advisory board) from Corcept Therapeutics, Indivior, and Liva Nova.